AveXis (NASDAQ: AVXS) and Dyax Corp. (NASDAQ:DYAX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

94.9% of AveXis shares are held by institutional investors. 18.6% of AveXis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares AveXis and Dyax Corp.’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
AveXis N/A N/A -$83.01 million ($5.58) -17.24
Dyax Corp. N/A N/A N/A ($0.21) -181.14

Dyax Corp. is trading at a lower price-to-earnings ratio than AveXis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for AveXis and Dyax Corp., as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AveXis 2 2 12 0 2.63
Dyax Corp. 0 0 0 0 N/A

AveXis presently has a consensus target price of $109.88, indicating a potential upside of 14.24%. Given AveXis’ higher probable upside, equities analysts plainly believe AveXis is more favorable than Dyax Corp..


This table compares AveXis and Dyax Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AveXis N/A -49.27% -45.59%
Dyax Corp. -47.32% -14.86% -12.09%


AveXis beats Dyax Corp. on 5 of the 8 factors compared between the two stocks.

AveXis Company Profile

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

Dyax Corp. Company Profile

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.